Effect of chronic kidney disease on the healing of titanium implants

Bone

Volumn 56, Issue 2, 2013, Pages 410-415

  Zou, Huawei ^a   Zhao, Xuefeng ^a   Sun, Ningyuan ^a   Zhang, Shiwen ^a   Sato, Tadatoshi ^b   Yu, Haiyang ^a   Chen, Qianming ^a   Weber, Hans Peter ^c   Dard, Michel ^d   Yuan, Quan ^a,b   Lanske, Beate ^b  

^a SICHUAN UNIVERSITY   (China)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Bone mineralization; Chronic kidney diseases; Dental implants; Fibroblast growth factor 23 (FGF23); Osseointegration; Parathyroid hormone (PTH)

Indexed keywords

ALIZARIN RED S; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE; TITANIUM; TRANSCRIPTION FACTOR OSTERIX; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; BONE STRENGTH; CHRONIC KIDNEY DISEASE; FEMALE; FEMUR IMPLANT; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MORPHOMETRICS; MOUSE; NEPHRECTOMY; NONHUMAN; OSSIFICATION; POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; UREMIA; WOUND HEALING;

BONE MINERALIZATION; CHRONIC KIDNEY DISEASES; DENTAL IMPLANTS; FIBROBLAST GROWTH FACTOR 23 (FGF23); OSSEOINTEGRATION; PARATHYROID HORMONE (PTH);

ANIMALS; DENTAL IMPLANTS; FEMALE; FIBROBLAST GROWTH FACTORS; MICE; MICE, INBRED C57BL; OSSEOINTEGRATION; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; TITANIUM; UREMIA;

EID: 84881227197     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.07.014     Document Type: Article

References (28)

1. Saran R., Hedgeman E., Huseini M., Stack A., Shahinian V. Surveillance of chronic kidney disease around the world: tracking and reining in a global problem. Adv Chronic Kidney Dis 2010, 17:271-281.
2. Gilbertson D.T., Liu J., Xue J.L., Louis T.A., Solid C.A., Ebben J.P., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736-3741.
3. Levey A.S., Atkins R., Coresh J., Cohen E.P., Collins A.J., Eckardt K.U., et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72:247-259.
4. Hallan S.I., Coresh J., Astor B.C., Asberg A., Powe N.R., Romundstad S., et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006, 17:2275-2284.
5. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
6. Zhang L., Wang F., Wang L., Wang W., Liu B., Liu J., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012, 379:815-822.
7. Pelletier S., Chapurlat R. Optimizing bone health in chronic kidney disease. Maturitas 2010, 65:325-333.
8. Ott S.M. Bone disease in CKD. Curr Opin Nephrol Hypertens 2012, 21:376-381.
9. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
10. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009, S1-S130. [Suppl.].
11. Lee M.M., Chu E.Y., El-Abbadi M.M., Foster B.L., Tompkins K.A., Giachelli C.M., et al. Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol 2010, 81:300-309.
12. Chen L.P., Chiang C.K., Chan C.P., Hung K.Y., Huang C.S. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients?. Am J Kidney Dis 2006, 47:815-822.
13. Naugle K., Darby M.L., Bauman D.B., Lineberger L.T., Powers R. The oral health status of individuals on renal dialysis. Ann Periodontol 1998, 3:197-205.
14. Craig R.G., Kotanko P., Kamer A.R., Levin N.W. Periodontal diseases-a modifiable source of systemic inflammation for the end-stage renal disease patient on haemodialysis therapy?. Nephrol Dial Transplant 2007, 22:312-315.
15. Cengiz M.I., Sumer P., Cengiz S., Yavuz U. The effect of the duration of the dialysis in hemodialysis patients on dental and periodontal findings. Oral Dis 2009, 15:336-341.
16. Borawski J., Wilczynska-Borawska M., Stokowska W., Mysliwiec M. The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients. Nephrol Dial Transplant 2007, 22:457-464.
17. Stellingsma C., Vissink A., Meijer H.J., Kuiper C., Raghoebar G.M. Implantology and the severely resorbed edentulous mandible. Crit Rev Oral Biol Med 2004, 15:240-248.
18. Dijakiewicz M., Wojtowicz A., Dijakiewicz J., Szycik V., Rutkowski P., Rutkowski B. Is implanto-prosthodontic treatment available for haemodialysis patients?. Nephrol Dial Transplant 2007, 22:2722-2724.
19. Gagnon R.F., Gallimore B. Characterization of a mouse model of chronic uremia. Urol Res 1988, 16:119-126.
20. Sun N., Zou H., Yang L., Morita K., Gong P., Shiba T., et al. Inorganic polyphosphates stimulate FGF23 expression through the FGFR pathway. Biochem Biophys Res Commun 2012, 428:298-302.
21. Xu B., Zhang J., Brewer E., Tu Q., Yu L., Tang J., et al. Osterix enhances BMSC-associated osseointegration of implants. J Dent Res 2009, 88:1003-1007.
22. El-Abbadi M.M., Pai A.S., Leaf E.M., Yang H.Y., Bartley B.A., Quan K.K., et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009, 75:1297-1307.
23. Alem A.M., Sherrard D.J., Gillen D.L., Weiss N.S., Beresford S.A., Heckbert S.R., et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000, 58:396-399.
24. Cozzolino M., Dusso A.S., Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001, 12:2511-2516.
25. Yoshiko Y., Wang H., Minamizaki T., Ijuin C., Yamamoto R., Suemune S., et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007, 40:1565-1573.
26. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010, 61:91-104.
27. Shalhoub V., Ward S.C., Sun B., Stevens J., Renshaw L., Hawkins N., et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011, 89:140-150.
28. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schuler C., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:e1000154.